All In Biotech

Drug Trial Radar · NCT04651634

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients

A Phase 2, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of MIT-001 in Prevention of Oral Mucositis in Patients Receiving CCRT for Locally Advanced HNSCC

Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 21, 2021

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
MitoImmune TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The proposed study in patients with previously untreated locally advanced head and neck squamous cell carcinoma (HNSCC) is designed to evaluate the efficacy and safety of three different doses of MIT-001 compared to the placebo in prevention of oral mucositis (OM) in patients with HNSCC who are undergoing concurrent chemoradiotherapy (CCRT).

Conditions

  • Head and Neck Squamous Cell Carcinoma
  • Oral Mucositis

Interventions

  • MIT-001 plus CCRTDrug

    MIT-001 IV-infusion plus CCRT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of severe OMTime frame: From first treatment to 2 months of safety follow-up period after CCRT completion

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Norris Comprehensive Cancer Center

    Los Angeles, California

  • Cancer Center of Kansas

    Wichita, Kansas

  • James P. Wilmot Cancer Center

    Rochester, New York

  • Wake Forest Baptist Health - Comprehensive Cancer Center

    Winston-Salem, North Carolina

  • James Cancer Hospital Solove Research Institute

    Columbus, Ohio

  • Keimyung University Dongsan Hospital

    Daegu, South Korea

  • Chungnam National University Hospital

    Daejeon, South Korea

  • National Cancer Center

    Goyang-si, South Korea

  • Seoul National University Bundang Hospital

    Gyeonggi-do, South Korea

  • Inha University Hospital

    Incheon, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Hanyang University Seoul Hospital

    Seoul, South Korea

  • The Catholic University of Korea Saint Vincent's Hospital

    Suwon, Gyeonggi-do, South Korea

  • Jeonbuk National University Hospital

    Jeonju, Jeollabuk-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.